Search clinical trials for: Several tumor types eligible

Total 33686 results

Ludwig Institute for Cancer Research
NYU Langone Health

Completed

NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors

Tumors

United States
Shanghai Bovax Biotechnology Co., Ltd.

Not yet recruiting

A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males

Anal Cancer | HPV-Related Carcinoma | Penile Cancer | Genital Wart | AIN3 | AIN2 | PIN-1 | AIN1 | PIN2 | PIN3

China
First Affiliated Hospital of Fujian Medical University

Recruiting

68Ga-JH04 PET/CT in Patients With Various Types of Cancer

Tumor

China
First Affiliated Hospital of Fujian Medical University

Recruiting

68Ga-DOTA-NI-FAPI04 PET/CT in Patients With Various Types of Cancer

Tumor

China
Merck Sharp & Dohme LLC

Recruiting

A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)

Melanoma | Renal Cell Carcinoma | Non-Small Cell Lung Cancer

Poland, United States, Argentina, Chile, Japan, Australia, France, New Zealand, South Africa, Turkey
Sichuan Provincial People's Hospital

Recruiting

18F-FAPI-RGD PET/CT in Various Tumor Types

Neoplasms

China
Regeneron Pharmaceuticals

Recruiting

A Trial to Learn if Odronextamab is Safe and Well-tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma (OLYMPIA-1)

Follicular Lymphoma (FL)

United States, Spain, Taiwan, Israel, Switzerland, Poland, Austria, Turkey, Italy, United Kingdom, Czechia, Australia, Chile
Cancer Institute and Hospital, Chinese Academy...
Peking University; Peking University Cancer Hospital & Institute

Recruiting

68Ga-TCR-FAPI PET/CT in Patients With Various Types of Cancer

Malignant Tumor | Positron Emission Tomography | Fibroblast Activation Protein Inhibitor

China
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types

Metastatic Melanoma | Stage III Lung Cancer AJCC v8 | Metastatic Lung Carcinoma | Stage IV Lung Cancer AJCC v8 | Locally Advanced Malignant Solid Neoplasm | Locally Advanced Melanoma | Metastatic Malignant Solid Neoplasm | Clinical Stage III Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma... and other conditions

United States
Eli Lilly and Company

Recruiting

A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer (CAMPFIRE)

Adolescent | Neoplasms | Child

United States, Spain, United Kingdom, Australia, Italy, Japan, Belgium, France, Germany
CJ Bioscience, Inc.

Recruiting

Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer

Melanoma | NSCLC | Metastatic Cancer | Advanced Solid Tumor | Advanced Cancer | HNSCC

Korea, Republic of
Biocad

Recruiting

A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma (NEO-MIMAJOR)

Melanoma (Skin) | Melanoma Stage III

Russian Federation, Belarus
Iovance Biotherapeutics, Inc.

Recruiting

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

Melanoma | Metastatic Melanoma | Unresectable Melanoma

United States, Spain, Australia, France, Netherlands, Italy, Canada, Sweden
Peking Union Medical College Hospital

Recruiting

68Ga-DOTA-F2 PET/CT in Patients With Various Types of Cancer

Tumor, Solid

China
Omega Therapeutics

Recruiting

A Phase 1/2 Study to Evaluate OTX-2002 in Patients With Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association With the MYC Oncogene (MYCHELANGELO I)

Hepatocellular Carcinoma | Solid Tumor | Liver Cancer | Hepatocellular Carcinoma Non-resectable | Hepatocellular Cancer | Hepatocellular Carcinoma Recurrent | Liver, Cancer of, Non-Resectable

United States, Hong Kong, Korea, Republic of, Singapore, Taiwan
Boehringer Ingelheim

Recruiting

A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)

Solid Tumors

Spain, Japan, United Kingdom, United States
Toray Industries, Inc

Recruiting

A Study of TRK-950 in Patients With Advanced Solid Tumors

Solid Tumor

Japan
Iovance Biotherapeutics, Inc.

Recruiting

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

Metastatic Melanoma | Unresectable Melanoma | Stage IV Non-small Cell Lung Cancer | Stage III Non-small Cell Lung Cancer

United States
Boehringer Ingelheim

Recruiting

A Study to Test Different Doses of BI 1831169 Alone and in Combination With Ezabenlimab in People With Different Types of Advanced Cancer (Solid Tumors)

Solid Tumors

United States, Spain, Germany, Austria, France, Belgium
Boehringer Ingelheim

Recruiting

A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab

Melanoma | Non-small Cell Lung Cancer (NSCLC) | Carcinoma, Squamous Cell of Head and Neck (HNSCC)

Netherlands
M.D. Anderson Cancer Center
Eisai Inc.

Recruiting

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases

Tumor | Brain Metastases

United States
University of Florida
Genentech, Inc.; Aveo Oncology Pharmaceuticals

Recruiting

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

Soft Tissue Sarcoma | Breast Cancer | Pancreatic Adenocarcinoma | Ovarian Cancer | Prostate Cancer | Neuroendocrine Tumors | Vulvar Cancer | Bile Duct Cancer | Gall Bladder Cancer

United States
Tarus Therapeutics, Inc.

Not yet recruiting

TT-4 as a Single Agent in Subjects With Advanced Selected Solid Tumors

Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer
Xian-Jun Yu

Not yet recruiting

Neuroendocrine Neoplasm Based on Multi-omics Integrated Analysis

Neuroendocrine Neoplasm

China
Boehringer Ingelheim

Recruiting

A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

Neoplasm Metastasis | Non-Small Cell Lung Cancer

United States, Hong Kong, Spain, Korea, Republic of, China, Israel, Germany, Japan, Singapore, Australia, United Kingdom, Austria, Netherlands, France, Portugal, Sweden, Italy, Belgium
Federal Research Institute of Pediatric Hematology...

Recruiting

DWI in the Diagnosis of Histological Types of Nephroblastoma in Children

Nephroblastoma (Wilms Tumour)

Russian Federation
SOLTI Breast Cancer Research Group
Novartis

Recruiting

Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors (ACROPOLI)

Melanoma | Sarcoma | Small Cell Lung Cancer | Hepatocellular Carcinoma | Pancreatic Adenocarcinoma | Uterine Carcinosarcoma | Mesothelioma | Cholangiocarcinoma | Lung Adenocarcinoma | Triple Negative Breast Cancer | Epithelial Ovarian Cancer | HER2-positive Breast Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal... and other conditions

Spain
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Recruiting

Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
Regeneron Pharmaceuticals

Recruiting

A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers (COMBINE-EGFR-1)

Advanced Solid Tumors

United States, Spain, Turkey, France
Assistance Publique - Hôpitaux de Paris

Recruiting

Innovative SonoCloud-9 Device for Blood Brain Barrier Opening in First Line Temozolomide Glioblastoma Patients. (SonoFIRST)

Initial Radiological Diagnosis Eligible for Tumor Resection | Initial Radiological Diagnosis Compatible With Newly Diagnosed Glioblastoma (IDH Wild-type) | Eligible for the Standard of Care Including Concurrent Temoradiation and Adjuvant Temozolomide

Belgium, France, Switzerland
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Major Complication Rate in Cancer Patients With Neutropenic Fever Potentially Eligible for a Hospital at Home Program

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm

United States
Memorial Sloan Kettering Cancer Center
Actinium Pharmaceuticals

Recruiting

Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Diffuse Large B-cell Lymphoma | B-ALL | DLBCL | DLBCL, Nos Genetic Subtypes | B ALL | Dlbcl-Ci | DLBCL Unclassifiable | DLBCL Activated B-Cell Type | DLBCL Germinal Center B-Cell Type | HGBL | HGBL, Nos

United States
First Affiliated Hospital of Fujian Medical University

Recruiting

68Ga-FAPI PET/CT in Patients With Various Types of Cancer

Metastasis | Tumor | Positron-Emission Tomography

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy (PYRAMID-1)

Non-squamous NSCLC | HER2 Exon 20 Mutation

Korea, Republic of, United States, Taiwan, Belgium, Spain, China, Australia, Turkey, Italy, France, Germany, Poland, Russian Federation
Shanghai Bovax Biotechnology Co., Ltd.

Recruiting

Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Cervical Cancer | Vulvar Cancer | Vaginal Cancer | CIN1 | CIN2 | CIN3 | VaIN1 | VaIN2 | VaIN3 | Genital Wart | VIN 1 | VIN 2 | VIN 3 | AIS

China
The First Affiliated Hospital of Xiamen University

Recruiting

Comparison of FDG and FAPI in Patients With Various Types of Cancer

Metastasis | Positron-Emission Tomography | Tumor, Solid

China
Eisai Inc.
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Solid Tumor

United States, Spain, United Kingdom, France
SpeciCare
University of Washington; Georgia Institute of Technology; Predictive Oncology; Netnoid... and other collaborators

Recruiting

The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology) (PIONEER)

Melanoma | Sarcoma | Renal Cell Carcinoma | Breast Cancer | Hepatocellular Carcinoma | Transitional Cell Carcinoma | Glioblastoma Multiforme | Cholangiocarcinoma | Small-cell Lung Cancer | Oligodendroglioma | Cancer of Head and Neck | Cancer of Liver | Cancer of Pancreas | Cancer of Brain and Nervous System | Adrenal... and other conditions

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors

Lung Cancer | Metastatic Cancer | Bladder Cancer | Renal Cancer | Melanoma Cancer | Head/Neck Cancers

United States
Merck Sharp & Dohme LLC

Recruiting

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Solid Tumors | Hematologic Malignancies

United States, Poland, Brazil, Ukraine, Argentina, Australia, Austria, Belgium, Canada, Chile, China, Colombia, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Israel, Italy, Japan, Korea, Republic... and more
Boehringer Ingelheim

Recruiting

This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)

Neoplasms

Belgium, Korea, Republic of, United States, Spain, Germany, Japan, Poland, Israel, Sweden, Denmark, Canada
Apollomics Inc.

Recruiting

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA)

Gastric Cancer | Pancreatic Cancer | NSCLC | Lung Cancer | Brain Tumor | Glioblastoma Multiforme | Advanced Cancer | Colon Cancer | Solid Tumors | Thyroid Cancer | Renal Cancer | Gastroesophageal Junction Adenocarcinoma | EGFR Gene Mutation | MET Amplification | HGF | MET Alteration | MET Fusion | Exon 14 Skipping

United States, Spain, France, United Kingdom, Taiwan, Australia, Finland, Italy, Singapore, Hungary, Canada, Puerto Rico, Russian Federation
European Organisation for Research and Treatment...

Recruiting

SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access (SPECTA)

All Tumor Types

Spain, United Kingdom, Croatia, Belgium, France, Netherlands, Italy, Germany, Portugal, Austria, Cyprus, Czechia, Estonia, Greece, Lithuania, Poland, Romania, Slovenia, Switzerland, Serbia
National Taiwan University Hospital
National Health Research Institutes, Taiwan

Recruiting

Harmonics-based in Vivo Optical Virtual Biopsy

Healthy Participants With Different Skin Types and Different Ages | Diseased Participants With Different Skin Types and Different Ages | Participants Suffered From Diabetes With Different Skin Types and Different Ages

Taiwan
National Cancer Institute (NCI)

Recruiting

Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer

Colorectal Neoplasms | Cholangiocarcinoma | Bile Duct Cancer | Pancreas Cancer | Gastric Neoplasms

United States
Centre Leon Berard

Recruiting

Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer (PROFILER)

Neoplasms

France
Mirati Therapeutics Inc.

Active, not recruiting

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-12)

Advanced Non Small Cell Lung Cancer | Metastatic Non Small Cell Lung Cancer

United States, Spain, Belgium, France, Germany, Hungary, Italy, United Kingdom, Korea, Republic of, Poland, Australia, Switzerland, Singapore, Netherlands, Romania, Czechia, Greece, Ireland, Austria, Russian Federation, Portugal, Hong... and more
M.D. Anderson Cancer Center
MedImmune LLC

Completed

Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes

Advanced and/or Metastatic Sarcoma

United States
Janssen Research & Development, LLC

Active, not recruiting

A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations (THOR)

Urothelial Cancer

Korea, Republic of, United States, Italy, Spain, Japan, United Kingdom, Belgium, Israel, China, Austria, France, Canada, Taiwan, Turkey, Germany, Russian Federation, Bulgaria, Poland, Greece, Brazil, Netherlands, Australia, Argentina, Mexic... and more
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany; GORTEC (Head and Neck Oncology and Radiotherapy...

Active, not recruiting

A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

Squamous Cell Carcinoma of the Head and Neck

United States, Spain, Korea, Republic of, Taiwan, China, Argentina, France, Japan, Israel, United Kingdom, Belgium, Germany, Portugal, Greece, Italy, Georgia, Australia, Czechia, Brazil, Canada, Austria, Russian Federation, Switzerland and more

Search clinical trials for: Several tumor types eligible

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations